Insomnia
Drug research and approvals for insomnia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 426 studies of insomnia are recruiting on ClinicalTrials.gov, Health Canada has authorized 18 drug trials for it since 2013, and the EU has 4 authorised medicines for it.
- Recruiting worldwide: 426
- Trials authorized in Canada: 18
- FDA orphan approvals: 0
- EU medicines: 4
Recruiting now
Newest start dates first, of 426 recruiting on ClinicalTrials.gov ↗- Intradialytic Benson's Relaxation Technique in Patients With Chronic Kidney DiseaseNCT07935980 · Not applicable · Cairo University · starts Dec 1, 2026
- Effect of Cyclic Sighing Breathing Exercise on CRBD, Pain, and Sleep Quality in Patients Undergoing TURNCT07843602 · Not applicable · Mersin University · starts Nov 5, 2026
- Effects of a Hemp Seed-based Product on Appetite and Health ParametersNCT07917130 · Not applicable · Halic University · starts Nov 2, 2026
- Asprosin and miRNA Expression in Young Women With Metabolic SyndromeNCT07917364 · Not reported · University of Applied Sciences in Nowy Targ · starts Nov 1, 2026
- Time-Restricted Eating and Personalized Energy-Restricted Diet in Obese Postmenopausal WomenNCT07874399 · Not applicable · Gazi University · starts Nov 1, 2026
- The Effect of the 4-7-8 Breathing Exercise on Stress, Resilience, and Sleep Quality in First-Year University StudentsNCT07938879 · Not applicable · Eastern Mediterranean University · starts Nov 1, 2026
- Association Between Sleep Quality and Self-Care in Heart Failure PatientsNCT06747689 · Not reported · Dokuz Eylul University · starts Nov 1, 2026
- A Trial to See if Daridorexant Can Help Adults and Elderly People With Insomnia Sleep Better During the Night and…NCT07843329 · Phase 3 · Idorsia Pharmaceuticals Ltd. · starts Oct 28, 2026
- Haelan 951 for Menopause Symptoms in Peri- and Postmenopausal WomenNCT07751029 · Not applicable · Spectrum Clinical Research, LLC · starts Oct 26, 2026
- Developing a Biopsychosocial Prediction Model for Running-Related InjuriesNCT07929311 · Not reported · National Yang Ming Chiao Tung University · starts Oct 24, 2026
How its trials ended
1,128 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 253 whose ending is known, 66% met their primary endpoint, 5% missed it and 29% stopped early.
- Completed, result not reported48543%
- Ongoing27024%
- Met its primary endpoint16715%
- Status unknown12011%
- Stopped: other or unclear424%
- Stopped: enrollment or feasibility182%
- Missed its primary endpoint121%
- Stopped: sponsor or business decision91%
- Stopped: funding40%
- Stopped: lack of efficacy10%
Trials authorized in Canada
The 10 newest of 18; search them all in Canada trials| Jul 28, 2026 | An open-label, long-term extension study to investigate the safety, tolerability, and durability of treatment effect of alks 2680 in participants with…Alixorexton (alks 2680) | Alkermes | Pending |
| Jul 18, 2025 | Double blind clinical trial of daridorexant for Alzheimer disease preventionDaridorexant | Douglas Mental Health University Institute | Ongoing |
| Jun 19, 2025 | Efficacy of trazodone in the treatment of insomnia in elderly people - a randomized controlled trial (tradition study)Trazodone | Santé Québec- Centre Hospitalier De L’université De Montréal | Ongoing |
| May 8, 2024 | Lemborexant for the treatment of residual insomnia in adequately treated major depressive disorder: a pilot randomized controlled trialLemborexant | St Michaels Hospital | Pending |
| Feb 23, 2024 | Cognitive behavioral therapy and trazodone effects on sleep and blood pressure in insomnia phenotypes based on objective sleep duration: a sequential…Trazodone | Centre De Recherche Cervo, Université Laval | Ongoing |
| Dec 20, 2023 | Lemborexant treatment of insomnia linked to epilepsyLemborexant | University of Manitoba | Ongoing |
| Jun 29, 2023 | The effects of lemborexant on the ability to sleep during daytime: a feasibility study to evaluate the potential of lemborexant to treat shift work disorderLemborexant | Ciusss Du Nord-De-L'Ile-De-Montréal - Hôpital Du Sacré-Coeur De Montréal. | Closed |
| Aug 16, 2021 | A pilot, double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of a cannabis-infused oil for treatment of insomnia in major…Cannabis (CANNABIDIOL-DELTA-9-TETRAHYDROCANNABINOL) | St. Joseph's Healthcare Hamilton | Ongoing |
| Jun 25, 2021 | Safety and efficacy of mirtazapine for treating chronic insomnia in the elderlyMirtazapine | Santé Québec- Centre Hospitalier De L’université De Montréal | Pending |
| Oct 7, 2020 | A double-blind, randomized, parallel-group study with quetiapine extended release as comparator to evaluate the efficacy and safety of seltorexant 20 mg as…JNJ-42847922 (seltorexant)/ Quetiapine | Johnson & Johnson | Closed |
Medicines authorised in the EU
Newest first| Nov 7, 2022 | Melatonin NeurimMelatonin | RAD Neurim Pharmaceuticals EEC SARL | EMA ↗ |
| Apr 29, 2022 | QuviviqDaridorexant | Idorsia Pharmaceuticals Deutschland GmbH | EMA ↗ |
| Sep 20, 2018 | SlenytoMelatonin | RAD Neurim Pharmaceuticals EEC SARL | EMA ↗ |
| Jun 29, 2007 | CircadinMelatonin | RAD Neurim Pharmaceuticals EEC SARL | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA